دورية أكاديمية

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

التفاصيل البيبلوغرافية
العنوان: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial
المؤلفون: Yu-zhou Gui, Wei Wang, Qing-qing Wu, Qi-chen Ding, Hong-jie Qian, Qiu-bei Lu, Ying-jun Zhang, Yu-lei Zhuang, Li Deng, Ying-lin Zuo, Lin Luo, Jing-ying Jia
المصدر: Frontiers in Pharmacology, Vol 15 (2024)
بيانات النشر: Frontiers Media S.A., 2024.
سنة النشر: 2024
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: HEC95468, soluble guanylate cyclase stimulator, safety, pharmacokinetics, pharmacodynamics, healthy volunteers, Therapeutics. Pharmacology, RM1-950
الوصف: Heart failure is the most costly cardiovascular disorder. New treatments are urgently needed. This study aims to evaluate the safety, pharmacokinetics, and pharmacodynamic profile of HEC95468, a soluble guanylate cyclase (sGC) stimulator, in healthy volunteers. Sixty-two, eighteen, and forty-eight participants were enrolled in the single ascending dose (SAD) study, the food effect (FE) study, and the multiple ascending dose (MAD) study, respectively. The study conforms to good clinical practice and the Declaration of Helsinki. Overall, HEC95468 was safe and tolerable; a higher proportion of HEC95468-treated participants reported mild headaches, dizziness, decreased blood pressure, increased heart rate, and gastrointestinal-related treatment-emergent adverse events (TEAEs), similar to the sGC stimulators riociguat and vericiguat. In terms of pharmacokinetic parameters, the maximum observed plasma concentration (Cmax) and the area under the concentration-time curve (AUC0-t) were dose-proportional over the dose range. Moderate accumulation was observed after multiple administrations of HEC95468. Systolic blood pressure (SBP) and diastolic blood pressure decreased, while 3′,5′-cyclic guanosine monophosphate (cGMP) concentration in plasma increased and heart rate was induced. Vasoactive hormones (renin, angiotensin II, and norepinephrine) in plasma were compensatorily elevated after oral administration. These data supported further clinical trials of HEC95468 in the treatment of heart failure and pulmonary arterial hypertension.Systematic Review Registration:http://www.chinadrugtrials.org.cn, identifier CTR20210064.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1359939/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2024.1359939
URL الوصول: https://doaj.org/article/471eb2450690481191e91200a2f0c4db
رقم الأكسشن: edsdoj.471eb2450690481191e91200a2f0c4db
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16639812
DOI:10.3389/fphar.2024.1359939